

Grant Cycle 1 Year 1	Project Title	Principal Investigator	Institution
1/03-12/03	Phase II study of transdermal estrogen in Androgen-Independent Prostate Cancer (AIPC)	Tomasz Beer, MD	OHSU
1/03-12/03	Evaluation of effects of human cachexia-associated protein on muscle and tumor cells	Eva Corey, PhD	UW
1/03-12/03	The role of bone-related factors in modulating androgen receptor activity and in progression of prostate cancer	Paul Rennie, PhD	UBC
1/03-12/03	The mechanism of chromosomal instability in human prostate cancer	Jeffrey Virgin, MD, PhD	PSHS-VA
Yr 2			
1/04-12/04	Histone methyltransferases and other chromatin modifying enzymes as a therapeutic target in prostate cancer: a chemical genetic approach	Antonio Bedalov, MD, PhD	FHCRC
1/04-12/04	Androgen related proteins as predictors of response to androgen-ablative therapy and markers for PSA recurrence	Beatrice Knudsen, MD, PhD	FHCRC
1/04-12/04	Role of infiltrating lymphocytes in androgen ablation induced apoptosis of prostate tumors	Colleen Nelson, PhD	UBC
1/04-12/04	Development of immortalized cell lines from Ashkenazi Jewish hereditary prostate cancer families	Elaine Ostrander, PhD	FHCRC
1/04-12/04	Gene expression profiling of telomerase-regulated genes in prostate cells	James Roberts, PhD	FHCRC
Yr 3			
1/05-12/05	Prostate cancer chemoprevention with resveratrol: a preclinical study	Norm Greenberg, PhD	FHCRC
1/05-12/05	Effect of estrogen administration on immune effectors and expression of immunoregulatory molecules on human prostate tissue and prostate cancer	Bruce Montgomery, MD	UW
1/05-12/05	Pilot study to investigate selenoenzymes in prostate tissue	Ulrike Peters, PhD, MPH	FHCRC

1/05-12/05	Effect of shedding of immune stimulatory molecule MIC on prostate cancer progression	Jennifer Wu, PhD	UW
1/05-12/05	Serum and tissue expression of the immune stimulatory molecule MIC as a biomarker for prostate cancer	Jennifer Wu, PhD	UW
Yr 4			
1/06-12/06	Effects of zoledronic acid in combination with RAD001 and AEW541 on CaP	Eva Corey, PhD	UW
1/06-12/06	Random mutations in prostate cancer	Lawrence Loeb, MD, PhD	UW
1/06-12/06	Caveolin 1: A possible biomarker for prostate cancer progression	Janet Stanford, PhD	FHCRC
1/06-12/06	Identification of genes causally involved in prostate cancer using high throughput <i>in vivo</i> mutagenesis screen	Valeri Vasioukhin, PhD	FHCRC
Yr 5			
1/07-12/07	Positron Emission Tomography Imaging of Bone in Patients with Metastatic Prostate Cancer	Evan Yu, MD	FHCRC / SCCA
1/07-12/07	Characterizing microRNAs in Prostate Cancer	Muneesh Tewari, MD, PhD	FHCRC
1/07-12/07	GLI1 and GLI2 as Therapeutic Targets in Prostate Cancer	Alan So, MD	UBC
1/07-12/07	Assessment of Clinico-pathologic Correlation of Gene Fusion in Prostate Cancer	David Huntsman, MD	UBC
1/07-12/07	Characterization of Inflammatory Cell Types in Prostate Tissues	Jennifer Wu, PhD	UW